Showing 17,681 - 17,700 results of 105,541 for search '(( 5 ((nn decrease) OR (a decrease)) ) OR ( 50 ((mean decrease) OR (we decrease)) ))', query time: 1.05s Refine Results
  1. 17681

    Sensitivity of mean population biomass and cumulative harvest to initial biomass to the rate of demographic change due to climate impacts. by Jameal F. Samhouri (10136090)

    Published 2025
    “…For each simulation, mean biomass and cumulative harvest were calculated for the transient period from the year 1 to <i>t</i><sub>change</sub>. …”
  2. 17682

    Comparison of antibody persistency through one year between one-dose and two-dose regimens of Ad5-nCoV vaccine for COVID-19 by Jia-Lu Feng (16520451)

    Published 2023
    “…The two-dose Ad5-nCoV regimen with a 56-d interval had no effect on the persistence of neutralizing antibodies but slowed decay trend of RBD-binding antibodies.…”
  3. 17683

    Inhibitors of 5-LOX block TRPM7-mediated cell rounding. by Hsiang-Chin Chen (247146)

    Published 2010
    “…<p>(A) Application of the 5-LOX inhibitors NDGA (10 µM), AA861 (10 µM), and MK886 (10 µM) to 293-TRPM7 expressing cells reduced cell rounding. …”
  4. 17684

    DataSheet2_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

    Published 2021
    “…</p><p>Material and Methods: Using Markov model and network meta-analysis, we conducted separate cost-effectiveness analyses for cemiplimab, pembrolizumab and atezolizumab among advanced NSCLC patients with PD-L1 of at least 50% from the United States health care sector perspective. …”
  5. 17685

    DataSheet3_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

    Published 2021
    “…</p><p>Material and Methods: Using Markov model and network meta-analysis, we conducted separate cost-effectiveness analyses for cemiplimab, pembrolizumab and atezolizumab among advanced NSCLC patients with PD-L1 of at least 50% from the United States health care sector perspective. …”
  6. 17686

    DataSheet1_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

    Published 2021
    “…</p><p>Material and Methods: Using Markov model and network meta-analysis, we conducted separate cost-effectiveness analyses for cemiplimab, pembrolizumab and atezolizumab among advanced NSCLC patients with PD-L1 of at least 50% from the United States health care sector perspective. …”
  7. 17687

    DataSheet6_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

    Published 2021
    “…</p><p>Material and Methods: Using Markov model and network meta-analysis, we conducted separate cost-effectiveness analyses for cemiplimab, pembrolizumab and atezolizumab among advanced NSCLC patients with PD-L1 of at least 50% from the United States health care sector perspective. …”
  8. 17688

    DataSheet4_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

    Published 2021
    “…</p><p>Material and Methods: Using Markov model and network meta-analysis, we conducted separate cost-effectiveness analyses for cemiplimab, pembrolizumab and atezolizumab among advanced NSCLC patients with PD-L1 of at least 50% from the United States health care sector perspective. …”
  9. 17689
  10. 17690

    EGFR Signaling Regulates Maspin/SerpinB5 Phosphorylation and Nuclear Localization in Mammary Epithelial Cells by Mariana Tamazato Longhi (2889737)

    Published 2016
    “…<div><p>Maspin (SerpinB5) is a non-inhibitory serpin (<u>ser</u>ine <u>p</u>rotease <u>in</u>hibitor) with very diverse biological activities including regulation of cell adhesion, migration, death, control of gene expression and oxidative stress response. …”
  11. 17691

    Inhibition of human cytochromes P450 2A6 and 2A13 by flavonoids, acetylenic thiophenes and sesquiterpene lactones from Pluchea indica and Vernonia cinerea by Supattra Boonruang (4358479)

    Published 2017
    “…In this study, activity-guided isolation identified four flavonoids <b>1-4</b> (apigenin, luteolin, chrysoeriol, quercetin) from <i>Vernonia cinerea</i> and <i>Pluchea indica, </i>four hirsutinolide-type sesquiterpene lactones <b>5-8</b> from <i>V. cinerea</i>, and acetylenic thiophenes <b>9-11</b> from <i>P. indica</i> that inhibited CYP2A6- and CYP2A13-mediated coumarin 7-hydroxylation. …”
  12. 17692

    Coupled Human-Environment Dynamics of Forest Pest Spread and Control in a Multi-Patch, Stochastic Setting by Qasim Ali (802840)

    Published 2015
    “…The population of trees is distributed across 10 patches (parks) comprising a “low volume” partition of 5 patches that experience a low volume of park visitors, and a “high volume” partition of 5 patches experiencing a high visitor volume. …”
  13. 17693
  14. 17694
  15. 17695
  16. 17696
  17. 17697
  18. 17698

    Development of Nitric Oxide Releasing Oxoisoaporphines with Antidepressant Activities by Simultaneously Regulating MAO‑A and SERT by Peisen Zhong (13883434)

    Published 2024
    “…The occurrence of depression is closely related to the decrease in serotonin (5-HT) levels in the synaptic cleft. …”
  19. 17699
  20. 17700